Vidyasagar D, Maeta H, Raju T N, John E, Bhat R, Go M, Dahiya U, Roberson Y, Yamin A, Narula A
Pediatrics. 1985 Jun;75(6):1132-42.
As a prelude to clinical trials with a bovine surfactant (surfactant TA), in human infants with hyaline membrane disease, pulmonary and hemodynamic changes following its instillation in premature baboons were investigated. Baboons, delivered by cesarean section at 141 +/- 3.5 days (mean +/- SD, 77% gestation), were provided with intensive care. At 2 hours of age in one group (n = 10), 100 mg/kg of surfactant TA (reconstituted bovine surfactant, Tokyo Tanabe Co., Tokyo) was instilled into the lungs. Sequential measurements and monitoring of pulmonary and hemodynamic variables were carried out in these ten baboons and in a control group of five baboons for 16 hours, at which time the experiments were electively terminated. At birth, the pulmonary compliance, findings of chest radiographs, ratio of arterial PO2 to alveolar PO2, and respirator variables needed to maintain normal blood gas and acid base status were identical in both groups and indicative of severe hyaline membrane disease. Following surfactant instillation, the treated group demonstrated a rapid increase in PO2 with significantly improved ratio of arterial PO2 to alveolar PO2 (from a mean +/- SD pretreatment value of 0.21 +/- 0.11 to 0.45 +/- 0.11 by 16 hours). Pulmonary compliance improved similarly (from pretreatment value of 0.18 +/- 0.06 mL/cm H2O/kg to 0.27 +/- 0.09 mL/cm H2O/kg). Significant reduction in respirator support variables could be achieved in all treated animals; however, in the control animals, the pulmonary status worsened as evidenced by increasing mean airway pressure and respirator variables to keep normal blood gas and acid base status, thus worsening compliance. At autopsy, pulmonary pressure-volume curves were significantly different with large hysteresis obtained in the surfactant-treated group. Although no deleterious effect on hemodynamics was noted in surfactant TA-treated animals, a large patent ductus arteriosus was demonstrated by aortography. Increased lung blood flow, probably due to a large patent ductus arteriosus flow, was demonstrated by radiolabeled microsphere technique. The physiologic significance and clinical relevance of these findings in premature baboons treated with surfactant TA are discussed.
作为对牛肺表面活性物质(表面活性物质TA)进行临床试验的前奏,对患有透明膜病的人类婴儿进行研究,观察其在早产狒狒中滴注后肺部和血液动力学的变化。狒狒在141±3.5天(平均±标准差,妊娠77%)通过剖宫产分娩,并给予重症监护。一组(n = 10)在2小时龄时,将100mg/kg的表面活性物质TA(重组牛肺表面活性物质,东京田边制药公司,东京)滴入肺部。对这10只狒狒和5只狒狒的对照组进行16小时的肺部和血液动力学变量的连续测量和监测,此时实验被选择性终止。出生时,两组的肺顺应性、胸部X光片表现、动脉血氧分压与肺泡血氧分压之比以及维持正常血气和酸碱状态所需的呼吸变量相同,表明患有严重的透明膜病。滴注表面活性物质后,治疗组的血氧分压迅速升高,动脉血氧分压与肺泡血氧分压之比显著改善(从平均±标准差的治疗前值0.21±0.11升至16小时时的0.45±0.11)。肺顺应性也有类似改善(从治疗前值0.18±0.06mL/cm H₂O/kg升至0.27±0.09mL/cm H₂O/kg)。所有治疗动物的呼吸支持变量都有显著降低;然而,在对照动物中,肺部状况恶化,表现为平均气道压力和呼吸变量增加以维持正常血气和酸碱状态,从而使顺应性恶化。尸检时,肺压力-容积曲线有显著差异,表面活性物质治疗组出现较大滞后现象。虽然在表面活性物质TA治疗的动物中未观察到对血液动力学的有害影响,但主动脉造影显示有较大的动脉导管未闭。放射性微球技术显示肺血流量增加可能是由于大量动脉导管未闭血流所致。讨论了这些在用表面活性物质TA治疗的早产狒狒中的发现的生理意义和临床相关性。